secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001645666-25-000004
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar presents zetomipzomib safety update from PALIZADE Phase 2b lupus nephritis trial
--------------------------------------------------------------------------------

- KOL event hosted by William Blair covering zetomipzomib in autoimmune hepatitis and lupus nephritis.
- Safety update from PALIZADE Phase 2b trial (active lupus nephritis) disclosed at event; no specific data provided.
- No financial results, guidance changes, or regulatory decisions announced.
- Company undertakes no obligation to update the presentation materials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000164566625000004/0001645666-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000164566625000004/kzr-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001645666-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer